Compare TCBS & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCBS | IMMP |
|---|---|---|
| Founded | 1934 | 1987 |
| Country | United States | Australia |
| Employees | 71 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.6M | 58.2M |
| IPO Year | 2021 | 2012 |
| Metric | TCBS | IMMP |
|---|---|---|
| Price | $16.83 | $0.45 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 1.5K | ★ 21.8M |
| Earning Date | 04-24-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 327.27 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $445.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.10 | $0.29 |
| 52 Week High | $20.00 | $3.53 |
| Indicator | TCBS | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 33.72 |
| Support Level | $16.79 | $0.29 |
| Resistance Level | $17.13 | $1.05 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 65.63 | 14.24 |
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans, commercial real estate loans, and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer, and other.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.